Adrenocortical carcinoma

Annals of Oncology

Volumn 8, Issue 5, 1997, Pages 423-427

  Gicquel, C ^a   Baudin, E ^b   Lebouc, Y ^a   Schlumberger, M ^b  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adrenocortical carcinoma; Chemotherapy; Genetic abnormalities; Mitotane

Indexed keywords

ADENYLATE CYCLASE; AMINOGLUTETHIMIDE; ARGININE; CISPLATIN; CORTICOTROPIN; CYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDROCORTISONE; FLUOROURACIL; HYDROCORTISONE; KETOCONAZOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METYRAPONE; MIFEPRISTONE; MITOTANE; PROTEIN P53; SOMATOMEDIN B; SURAMIN;

ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ARTIFICIAL EMBOLISM; CANCER INCIDENCE; CARCINOGENESIS; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC DISORDER; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MULTIDRUG RESISTANCE; ONCOGENE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030859209     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008257530919     Document Type: Review

References (57)

1. Ross N, Aron D. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990; 323: 1401-5.
2. Luton JP, Cerdas S, Billaud L et al. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195-1202.
3. Venkatesh S. Hickey R, Sellin R et al. Adrenal cortical carcinoma. Cancer 1989; 64: 765-9.
4. Sabagga C. Avilla S, Schulz C et al. Adrenocortical carcinoma in children: Clinical aspects and prognosis. J Pediatr Surg 1993; 28: 841-3.
5. Teinturier C, Brugières L, Lemerle J et al. Corticosurénalomes de l'enfant: Analyse rétrospective de 54 cas. Arch Pédiatrie 1996; 3: 235-40.
6. Sotelo-Avila C, Gonzalez-Crussi F, Fowler J. Complete and incomplete forms of Beckwith-Wiedemann syndrome: Their oncogenic potential. J Pediatr 1980; 96: 47-50.
7. Malkin D, Li F, Strong L et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
8. Jensen J, Pass H, Sindelar W, Norton J. Recurrent or metasuitic disease in selected patients with adrenocortical carcinoma. Arch Surg 1991; 126:457-61.
9. Tartour E, Caillou B, Tenenbaum F et al. Immunohistochemical study of adrenocortical carcinoma: Predictive value of the D11 monoclonal antibody. Cancer 1993; 72: 3296-303.
10. Weiss L. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8: 163-9.
11. Weiss L, Medeiros J, Vickey A. Pathologic features of prognostic significance in adrenocortical carcinomas. Am J Surg Pathol 1989; 13: 202-6.
12. Aupetit-Faisant B, Battaglia C. Emeric-Blanchouin N, Legrand J. Hypo-aldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: A marker of adrenal carcinoma. J Clin Endocrinol Metab 1993; 76: 38-43.
13. Aupetit-Faisant B, Blanchouin-Emeric N, Tenenbaum F et al. Plasma levels of aldosterone versus aldosterone precursors: A french retrospective multicentric study. J Clin Endocrinol Metab 1995; 80: 2715-21.
14. Marx C. Wolkersdörfer G et al. MHC class II expression. A new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab 1996; 81: 4488-91.
15. Lyons J, Landis C, Harsh G et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655-9.
16. Reincke M, Karl M, Travis W, Chrousos G. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metab 1993; 77: 1419-22.
17. Gicquel C, Dib A, Bertagna X et al. Oncogenic mutations of a Gi2 protein are not determinant for human adrenocortical tumourigenesis. Eur J Endocrinol 1995; 133: 166-72.
18. Moul J, Bishoff J, Theune S, Chang E. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J Urol 1993; 149: 1389-94.
19. Yashiro T, Hara H, Fulton N et al. Point mutations of RAS genes in human adrenocortical tumors. Absence in adrenocortical hyperplasia. World J Surg 1994; 18: 455-61.
20. Yano T, Linehan M, Anglard P et al. Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst 1989; 81: 518-23.
21. Gicquel C, Bertagna X, Le Bouc Y. Recent advances in the pathogenesis of adrenocortical tumours. Eur J Endocrinol 1995; 133: 133-44.
22. Reincke M, Karl M, Travis W et al. p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78: 790-4.
23. Lin S, Lee Y, Tsai J. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 1994; 78: 483-91.
24. Makos Wales M, Biel M, El Deiry W et al. p53 activates expression of HlC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1995; 1: 570-7.
25. Goshen R, Rachmilewitz J, Schneider T et al. The expression of the H-19 and IGF-2 genes during human embryogenesis and placental development. Mol Reprod Dev 1993; 34: 374-9.
26. Voutilainen R, Ilvesmäki V. Ariel I et al. Parallel regulation of parentally imprinted H19 and insulin-like growth factor II genes in cultured human fetal adrenal cells. J Clin Endocrinol Metab 1994; 134: 2051-6.
27. Ilvesmäki V, Kahri A, Miettinen P, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: High IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993; 77: 852-8.
28. Gicquel C, Bertagna X, Schneid H et al. Rearrangements at 11p15 locus and overexpression of insulin like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994; 78: 1444-53.
29. Coppes M, Haber D, Grundy P. Genetic events in the development of Wilms' tumor. N Engl J Med 1994; 331: 586-90.
30. Hastie N. The genetics of Wilms' tumor. A case of disrupted development. Ann Rev Genet 1994; 28: 523-58.
31. Morison I, Becroft D, Taniguchi T et al. Somatic overgrowth associated with overexpression of insulin-like growth factor II. Nature Med 1996; 2: 311-6.
32. Le Roith D. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-9.
33. De Chiara T, Robertson E, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849-59.
34. Hao Y, Crenshaw T, Moulton T et al. Tumour-suppressor activity of H19 RNA. Nature 1993; 365: 764-7.
35. Matsuoka S, Edwards M, Bai C et al. p57 K1P2, a structurally distinct member of the p21CIP2 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650- 62.
36. Mong-Hong L, Reynisdottir I, Massagué J. Cloning of p57 KIP2, a cyclin dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639-49.
37. Overall M, Spencer J, Bakker M et al. p57KIP2 is expressed in Wilm's tumor with LOH of 11p15.5. Genes Chrom Cancer 1996; 17: 56-9.
38. Bodie B, Novick AC, Pontes JE et al. The Cleveland clinic experience with adrenal cortical carcinoma. J Urol 1989; 141: 257-60.
39. Henley DJ, Van Heerden JA, Grant CS et al. Adrenal cortical carcinoma. A continuing challenge. Surgery 1983; 94: 926-31.
40. Icard P, Chapuis Y, Andreassian B et al. Adrenocortical carcinoma in surgically treated patients: A retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992; 112: 972-80.
41. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963-71.
42. Boven E, Vermorken JB, Van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with Op'-DDD. Cancer 1984; 3: 26-9.
43. Haak HR, Hermans J, Van de Velde CJH et al. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-51.
44. Robinson BG, Hales IB, Henniker AJ et al. The effect of Op'DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol 1987; 27: 437-44.
45. Chun HG, Yogoda A, Kemeny N. Cisplatinum for adrenal cortical carcinoma. Cancer Treat Rep 1983; 76: 513-4.
46. Hesketh PJ, Mc Caffrey RP, Finkel HE et al. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 1987; 71:222-4.
47. Tattersall MHN, Lander H, Bain B et al. Cisplatinum treatment of metaslatic adrenal carcinoma. Med J Aust 1980; 1: 419-21.
48. Bukowski RM, Wolfe M, Levine HS et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group Study. J Clin Oncol 1993; 11: 161-5.
49. Van Slooten H, Van Oosterom AT. CAP (Cyclophosphamide, Doxorubicin and Cisplatinum) Regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983; 67: 377-9.
50. Schlumberger M, Brugieres L, Gicquel C et al. Fluorouracil, Doxorubicin and Cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991; 67: 2997-3000.
51. Decker RA, Elson P, Hogan TF et al. for the Eastern Cooperative Oncology Group. Eastern Cooperative Oncology Group Study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991; 110: 1006-13.
52. Burgess MA, Legha SS, Sellin RV. Chemotherapy with cis-platinum and etoposide (VP16) for patients with advanced adrenal cortical carcinoma (ACC). Proc ASCO, J Clin Oncol 1993; 12: 188.
53. Bates SE, Shieh CY, Mickley LA et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (MDR-1/P-Glycoprotein) which is also expressed by adrenocortical carcinoma. J Clin Endocrinol Metab 1991; 73: 18-29.
54. Flynn SD, Murren JR, Kirby WM et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112: 981-6.
55. La Rocca RV, Stein CA, Danesi R et al. Suramin in adrenal cancer: Modulation of steroid hormone production. cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990; 71: 497-504.
56. ArIt W, Reincke M, Siekmann L et al. Suramin in adrenocortical cancer: Limited efficacy and serious toxicity. Clin Endocrinol 1994; 41: 299-307.
57. Dorfinger K, Niederle B, Vierhapper H et al. Suramin and the human adrenocortex: Results of experimental and clinical studies. Surgery 1991; 100: 1100-5.